AstraZeneca announced on June 26th that on June 18th, 2024, the China National Medical Products Administration approved the first-line therapy of Tagrisso combined with Pamiparib and platinum-based chemotherapy drugs for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have exon 19 deletion or exon 21 (L858R) substitution mutations in the epidermal growth factor receptor (EGFR).
阿斯利康肺癌靶向药泰瑞沙新适应症在中国获批
Astrazeneca's lung cancer targeted drug, Tagrisso, has been approved for new indications in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.